Evidence map›Paper›PMID 38406551›Full record

ArticleEJHaem2024

Prevalence and clinical impact of CD56 and T-cell marker expression in acute myeloid leukaemia: A single-centre retrospective analysis.

Inna Shaforostova, Simon Call, Georg Evers, Christian Reicherts, Linus Angenendt, Matthias Stelljes, Wolfgang E Berdel, Alexander Pohlmann, Jan-Henrik Mikesch, Frank Rosenbauer and 3 more

Open access · diamondAbstract read
In one paragraph

Article in EJHaem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Inna ShaforostovaDepartment of Medicine A University Hospital Münster Münster Germany.ORCID https://orcid.org/0000-0002-0592-091X
Simon CallDepartment of Medicine A University Hospital Münster Münster Germany.
Georg EversDepartment of Medicine A University Hospital Münster Münster Germany.
Christian ReichertsDepartment of Medicine A University Hospital Münster Münster Germany.
Linus AngenendtDepartment of Medicine A University Hospital Münster Münster Germany.ORCID https://orcid.org/0000-0003-2502-9910
Matthias StelljesDepartment of Medicine A University Hospital Münster Münster Germany.
Wolfgang E BerdelDepartment of Medicine A University Hospital Münster Münster Germany.ORCID https://orcid.org/0000-0002-3030-6567
Alexander PohlmannDepartment of Medicine A University Hospital Münster Münster Germany.
Jan-Henrik MikeschDepartment of Medicine A University Hospital Münster Münster Germany.
Frank RosenbauerInstitute of Molecular Tumor Biology Faculty of Medicine University of Münster Münster Germany.
Georg LenzDepartment of Medicine A University Hospital Münster Münster Germany.
Christoph SchliemannDepartment of Medicine A University Hospital Münster Münster Germany.ORCID https://orcid.org/0000-0003-1755-9583
Klaus WethmarDepartment of Medicine A University Hospital Münster Münster Germany.ORCID https://orcid.org/0000-0002-1899-3261
University Hospital Münster · DEETH Zurich · CHUniversity of Münster · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Flow cytometry-based immunophenotyping is a mainstay of diagnostics in acute myeloid leukaemia (AML). Aberrant CD56 and T-cell antigen expression is observed in a fraction subset of AML cases, but the clinical relevance remains incompletely understood. Here, we retrospectively investigated the association of CD56 and T-cell marker expression with disease-specific characteristics and outcome of 324 AML patients who received intensive induction therapy at our centre between 2011 and 2019. We found that CD2 expression was associated with abnormal non-complex karyotype,

Indexed as

acute myeloid leukaemiaCD56clinical impactflow cytometryT‐cell marker

Identifiers

PMID38406551
PMCPMC10887264
OpenAlexW4388961393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.